A cuproptosis-associated long non-coding RNA signature for lung squamous cell carcinoma prognosis and immunotherapy

Authors

  • Chunlan Hou Department of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China. https://orcid.org/0000-0002-1974-5104
  • Xiuping Wu Department of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China.
  • Caoyang Li Department of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan, China.
  • Chao Wang Department of Cardiothoracic Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
  • Jinbo Liu Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
  • Qing Luo Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. https://orcid.org/0000-0003-2596-8862

DOI:

https://doi.org/10.17305/bb.2022.8481

Keywords:

Lung squamous cell carcinoma, cuproptosis, long non-coding RNA, prognosis, immunotherapy

Abstract

Cuproptosis, a copper-induced mechanism of mitochondrial-related cell death, has been implicated as a breakthrough in the treatment of cancer and has become a new treatment strategy. Furthermore, long non-coding RNA (lncRNA) can change the biological activities of tumor cells. Worldwide, lung squamous cell carcinoma (LUSC) is among the most common annoying tumors. LncRNAs related to cuproptosis are not researched at LUSC. Our research intends to develop a signature on the basis of cuproptosis-associated lncRNAs, which can predict LUSC prognosis and investigate LUSC immunological features. The TCGA database was used to retrieve LUSC transcriptome, clinical, and gene mutation data. For statistical analysis, we utilized the R program. We created a signature consisting of three cuproptosis-related lncRNAs in this investigation (including AC002467.1, LINC01740, and LINC02345). Survival analyses and Receiver Operating Characteristic curves demonstrated that this signature possessed powerful predictive capability. The signature’s ability to predict was confirmed by a Receiver Operating Characteristic curve and principal component analysis. Notably, the patient with a high-risk score and a high tumor mutation burden level had a lower survival time. Furthermore, the tumor immune dysfunction and exclusion analysis showed that these individuals with low-risk scores may benefit from immunotherapy. The signature constructed by three cuproptosis-associated lncRNAs may be prognostic markers of LUSC. It contributes to immunotherapy and offers LUSC’s therapy a new treatment direction.

Downloads

Download data is not yet available.
A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma

Published

2023-01-15

How to Cite

1.
Hou C, Wu X, Li C, Wang C, Liu J, Luo Q. A cuproptosis-associated long non-coding RNA signature for lung squamous cell carcinoma prognosis and immunotherapy. Biomol Biomed [Internet]. 2023Jan.15 [cited 2023Feb.1];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/8481

Issue

Section

Molecular Biology